Barinthus Biotherapeutics (BRNS) Earnings Date, Estimates & Call Transcripts $0.99 -0.01 (-1.02%) Closing price 05/7/2025 03:59 PM EasternExtended Trading$0.92 -0.07 (-6.65%) As of 05/7/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Barinthus Biotherapeutics Earnings Summary Latest Q1 Earnings DateMay. 7EstimatedConsensus EPS (May. 7) -$0.34 Actual EPS (May. 7) -$0.49 Missed By -$0.15 Barinthus Biotherapeutics posted Q1 2025 earnings on May 7, 2025, reporting an EPS of -$0.49, which missed analysts' consensus estimates of -$0.34 by $0.15. With a trailing EPS of -$1.55, Barinthus Biotherapeutics' earnings are expected to grow next year, from ($1.38) to ($1.31) per share. Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K)SEC FilingPowered by Get Barinthus Biotherapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Barinthus Biotherapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBRNS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BRNS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Barinthus Biotherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.37-$0.28-$0.33Q2 20252-$0.37-$0.27-$0.32Q3 20252-$0.39-$0.27-$0.33Q4 20252-$0.39-$0.27-$0.33 Barinthus Biotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025-$0.34-$0.49 -$0.15-$0.49--3/20/2025Q4 2024-$0.50-$0.51 -$0.01-$0.51-$14.97M11/6/2024Q3 2024-$0.44-$0.21+$0.23-$0.21-$14.97M8/8/2024--$0.42-$0.43 -$0.01-$0.43--5/13/2024Q1 2024-$0.64-$0.40+$0.24-$0.40--3/20/2024Q4 2023-$0.55-$0.45+$0.10-$0.45--11/9/2023Q3 2023-$0.62-$0.37+$0.25-$0.37--8/10/2023Q2 2023-$0.59-$0.62 -$0.03-$0.62$0.65M$0.33M5/12/2023Q1 2023-$0.58-$0.48+$0.10-$0.48$1.12M$0.47M Barinthus Biotherapeutics Earnings - Frequently Asked Questions When did Barinthus Biotherapeutics announce their last quarterly earnings? Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earning data on Wednesday, May 7, 2025. Learn more on BRNS's earnings history. Did Barinthus Biotherapeutics beat their earnings estimates last quarter? In the previous quarter, Barinthus Biotherapeutics (NASDAQ:BRNS) missed the analysts' consensus estimate of ($0.34) by $0.15 with a reported earnings per share (EPS) of ($0.49). Learn more on analysts' earnings estimate vs. BRNS's actual earnings. How can I view Barinthus Biotherapeutics's earnings report? Barinthus Biotherapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Barinthus Biotherapeutics generate each year? Barinthus Biotherapeutics (NASDAQ:BRNS) has a recorded annual revenue of $14.97 million. How much profit does Barinthus Biotherapeutics generate each year? Barinthus Biotherapeutics (NASDAQ:BRNS) has a recorded net income of -$73.35 million. BRNS has generated -$1.55 earnings per share over the last four quarters. What is Barinthus Biotherapeutics's EPS forecast for next year? Barinthus Biotherapeutics's earnings are expected to grow from ($1.38) per share to ($1.31) per share in the next year. More Earnings Resources from MarketBeat Related Companies Greenwich LifeSciences Earnings FitLife Brands Earnings Theratechnologies Earnings Compugen Earnings Lyell Immunopharma Earnings Editas Medicine Earnings Protara Therapeutics Earnings Enanta Pharmaceuticals Earnings Neumora Therapeutics Earnings RAPT Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Disney Stock Jumps on Earnings—Is the Magic Sustainable?Archer Stock Eyes Q1 Earnings After UAE UpdatesFord Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostPalantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release? This page (NASDAQ:BRNS) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | SponsoredNew breed of trader (Wall Street hates us?)Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for tr...Timothy Sykes | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
